Yes Gary, the trend is toward being more liberal in approving treatments for more indications for reimbursement and coverage and for liberalizing how to justify expanding indications as well.
I don’t expect a huge challenge getting DCVax thought of as a therapeutic treatment for all solid tumors potentially. I expect the approval and then expansion beyond GBM to be substantially and meaningfully faster than some seem to be thinking, given that they seem to be expecting a very old fashioned and traditional approach. Laws have changed however, to make those expectations no longer the regulatory measure. New standards apply and will apply further.
I believe it is the blood supply to the Pancreas that spreads the cancer and feeds the tumor that makes pancreatic cancer so deadly. This said, I believe GBM tumors are more lethal. Thus, they are apples and oranges. Not to say DCVax-L would not work on both. We will know soon.
Market Data 
Markets 
AI
